Sunshine Biopharma Surges to 409th in Daily Rankings with $21.3 Million Turnover

On April 2, 2025, Sunshine Biopharma (SBFM) experienced a significant surge in trading volume, with a turnover of $21.3 million, marking a 5594.37% increase from the previous day. This substantial rise in trading activity placed SBFM at the 409th position in the daily stock market rankings. The company's stock price also saw a notable increase, rising by 8.17% over the past two days, with a cumulative gain of 17.80%.

Sunshine Biopharma has made significant strides in the development of mRNA therapy for cancer treatment. The company's K1.1-mRNA-LNP therapy has shown promising results in reducing the growth of human hepatocellular carcinoma (HCC) tumors in mice. Both the full-length and truncated versions of the therapy demonstrated good tolerability and efficacy in preclinical studies. The full-length K1.1c was found to reduce the growth of three different types of human HCC tumors in mice, while the truncated version K1.1d showed significant anti-tumor activity in a dose-dependent manner.

Sunshine Biopharma is currently conducting additional animal studies to optimize the dosing of the truncated version K1.1d and compare its therapeutic window with that of the full-length K1.1c. The smaller-sized mRNA of the truncated version offers the advantage of better efficacy at lower doses, which could potentially lead to more effective and cost-efficient treatments for cancer patients.

The company's CEO, Dr. Steve Slilaty, expressed optimism about the potential of mRNA-LNP therapy, stating that it represents a revolutionary way to treat cancer. The positive results of the K1.1-mRNA-LNP therapy to date have been remarkable, and the company is looking ahead to the opportunity of delivering new life-saving treatments for cancer patients around the world.